文献速递肝病消化道肿瘤与早癌

亚洲视角下的非酒精性脂肪性肝病相关肝细胞癌

Asian perspective on NAFLD-associated HCC.
PubMed 文献 · J Hepatol · 2021-10-04

综述指出亚洲非酒精性脂肪性肝病(NAFLD)人群患病率已达34%,NAFLD相关肝细胞癌(HCC)呈上升趋势。文章回顾近30年亚洲HCC流行病学变化,强调PNPLA3基因多态性在东亚人群尤为普遍,非肥胖者NAFLD常见,且NAFLD常未诊断导致HCC监测不足、确诊偏晚。尽管普遍接种乙肝疫苗约20-30年,慢性HBV感染仍流行,代谢因素与合并肝脂肪变对感染者HCC发生的重要性日益凸显。

要点

  • 亚洲NAFLD患病率34%,NAFLD相关HCC呈上升趋势。
  • PNPLA3多态性在东亚常见,可能增加HCC风险。
  • NAFLD常未诊断,HCC监测不足,确诊多为晚期。

核心结论

  • 亚洲NAFLD患病率34%,NAFLD相关HCC上升,传统风险因素外PNPLA3多态性在东亚尤为重要。
  • NAFLD常未诊断导致HCC监测不足、确诊偏晚,非肥胖者NAFLD常见。
  • 慢性HBV感染仍流行,代谢因素与合并肝脂肪变对感染者HCC发生重要。

研究设计与样本

  • 综述描述亚洲过去30年HCC流行病学变化,未报告系统检索策略。

主要发现

  • 亚洲NAFLD更新人群患病率为34%。
  • PNPLA3基因多态性在东亚尤为普遍,可能增加HCC风险。
  • NAFLD在非肥胖个体中在亚洲也常见。
  • NAFLD常未诊断,接受HCC监测者少,肝硬化以外监测人群界定不清。
  • NAFLD相关HCC常确诊于晚期,无法根治。

临床怎么用

  • 应提高对NAFLD的识别与诊断,以改善HCC监测覆盖。
  • 对NAFLD患者需关注PNPLA3多态性等遗传风险。
  • 非肥胖者NAFLD亦需重视HCC风险。
  • 慢性HBV感染者应关注代谢因素与肝脂肪变对HCC的影响。

局限性

  • 为综述,未报告系统检索策略与纳入标准。
  • 肝硬化以外HCC监测目标人群界定不清。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Recent data suggest that non-alcoholic fatty liver disease (NAFLD) has become a major public health problem in Asia, with an updated population prevalence of 34%. In parallel, NAFLD-associated hepatocellular carcinoma (HCC) is also on the rise. In this review, we describe the changing epidemiology of HCC in Asia over the past 30 years. While traditional risk factors for HCC (older age, male sex and metabolic factors) are also important in Asia, the PNPLA3 gene polymorphism is particularly prevalent in East Asia and may increase the risk of HCC. NAFLD among non-obese individuals is also commonly described in Asia. Because NAFLD is often undiagnosed, few patients receive HCC surveillance, and the target surveillance population beyond patients with cirrhosis remains poorly defined. As a result, NAFLD-associated HCC is often diagnosed at an advanced stage, rendering curative treatment impossible. Finally, despite around 20-30 years of universal vaccination, chronic HBV infection remains prevalent in Asia, and emerging evidence highlights the importance of metabolic factors and concomitant hepatic steatosis on HCC development in infected patients. Future studies should explore the role of metabolic treatments in HCC prevention among patients with hepatic steatosis and concomitant liver diseases.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Yip TC, Lee HW, Chan WK, et al. Asian perspective on NAFLD-associated HCC. J Hepatol. 2021. PMID: 34619251. doi:10.1016/j.jhep.2021.09.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。